177Lutetium-Peptide Receptor Radionuclide Therapy (PRRT) safety assessment in patients with refractory Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NETs)

#3516

Introduction: 177Lu-PRRT became an established therapeutic modality in inoperable or metastatic NETs, demonstrating substantial survival benefits and reassuring safety profile. Dosimetry of Organs-At-Risk [OAR, kidneys, bone marrow (BM) and spleen] and malignant lesions ensures to further optimize its safety and efficacy.

Aim(s): We prospectively evaluate all the Adverse Events of 177Lu-PRRT and whether potential myelotoxicity/nephrotoxicity correlates with OARs dosimetric data.

Materials and methods: 37 consecutive GEP-NET patients treated by 177Lu-PRRT were included on the study [NCT01842165]. According to CTCAE 4.03, all the AEs were collected retaining the highest grade. Haematological parameters (haemoglobin, thrombocyte, white blood/neutrophil and lymphocyte count) as well as GFR modifications between baseline and End Of Treatment were analysed for each patient. OARs dosimetry was performed for all subjects in every therapy cycle using three abdominal SPECT/CT and five blood samples.

Conference:

Presenting Author: van Bogaert C

Authors: van Bogaert C, Mileva M, Marin G, Levillain H, Artigas-Guix C,

Keywords: PRRT, Safety, Dosimetry, Prospective trial,